Giving New Life to Every Organ and Every Patient

Targa Biomedical is advancing organ rescue, transplantation, and regenerative medicine through cellular protection technologies

About Targa

Where science
meets clinical need

Targa Biomedical is a Montréal-based company developing ex vivo technologies for organ preservation and conditioning before transplantation, as well as cell preservation solutions. Founded in 2018 by Dr. Shant Der Sarkissian and Dr. Nicolas Noiseux, Targa is advancing TBM-005 toward a first-in-human clinical evaluation, initially in lung transplantation, with potential expansion to other organs. The company is also extending its platform into regenerative medicine through advanced cryopreservation and cell storage solutions for cell therapy and biomanufacturing.

Our mission

Access to transplantation is limited not only by the number of donors, but also by the quality of available organs.
Targa’s technology is designed to address this critical challenge.

Leadership

The team behind the science

Dr. Shant Der Sarkissian
PhD, MBA

Chief Executive Officer & Co-Founder

Pharmacologist and entrepreneur with expertise in translational product development, biomedical innovation, and business strategy. Adjunct Professor at Université de Montréal. University of Florida Fellow. Axis Lead, Pillar II, Quebec Cell, Tissue and Gene Therapy Network.

Dr. Nicolas Noiseux
MD, MSc

Chief Medical Officer & Co-Founder

Internationally recognized cardiac and transplant surgeon. Director of Cardiovascular Research at CHUM. Full Professor at Université de Montréal. Harvard Fellow. 225+ peer-reviewed publications. Principal investigator in first-in-human cell therapy trials for heart failure.

Advisory Board

Built on collaboration. Backed by expertise.

Dr. Pasquale Ferraro, MD
Medical & Scientific Advisor

Dr. Dan Chiche, MD
Medical & Regulatory Advisor

Dr. Pierre Caudrelier, MD
Medical & Regulatory Advisor

News & insights

  • June 20-24, 2026

    Targa Biomedial at the Americal Transplant Congress 

    Targa Biomedical will be attending the ATC 2026 in Boston.

  • August 2-6, 2025

    Targa Biomedial at the World Transplant Congress

    Targa Biomedical will be attending the WTC 2025 in San Francisco.

  • November 16-18, 2024

    Targa Biomedical selected as finalist in the Florida Innovation Conference

    BioFlorida pitch event (Finalist selected from 75+ applications).

Accelerators and Support
AdMare-bioinnovations Logo
CanExport Logo
CHUM Logo
crCHUM Logo
Economie Innovation Quebec Logo
MEDTEQ Logo
Mitacs Canada Logo
NRC Logo
PME MTL Logo

Accelerators,
grants & support

adMare Bioinnovations

Mayo Clinic Innovation Exchange

Mitacs

CIHR IRSC

CanExport

PME-MTL

NRC-CNRC

Économie et innovation Québec

MEDTEQ

Targa partners with preservation and perfusion technology companies, including platforms, devices, and solutions. If our tech could enhance your organ-recovery offering, let’s connect.

Targa partners with companies developing preservation and perfusion technologies, including platforms, devices and solutions. If our technology could enhance your offering in organ preservation, perfusion, or transplantation, let’s connect.